Luis-Emilio Garcia-Perez

13PUBLICATIONS
28CO-AUTHORS
PharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Economic models and forecastingEpidemiological modellingPharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Feb 04, 2026
A treat-to-target approach for obesity management: A post hoc analysis of the SURMOUNT-5 trial.

Carel W le Roux, Luca Busetto, Louis Aronne

|Jun 24, 2025
Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence.

Naveed Sattar, Luis-Emilio García-Pérez, Angel Rodríguez

|Jul 04, 2024
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.

Annabel Barrett, Kristina S Boye, Luis-Emilio García-Pérez

|Sep 15, 2023
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Final patient-reported outcomes at 24 months.

Kristina S Boye, Jérémie Lebrec, Anne Dib

|Sep 13, 2023
The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.

Francesco Giorgino, Bruno Guerci, Martin Füchtenbusch

|Jun 21, 2023
Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison.

Carel W le Roux, Emily R Hankosky, Duzhe Wang

Pageof 3

Frequent Collaborators

4 joint publications

Francesco Giorgino

2 joint publications

Axel Haupt

2 joint publications

Maria Yu

2 joint publications

Kristina S Boye